Click image to enlarge
The
U-PLEX platform offers validated components that can be combined to create high quality assays quickly and easily.
U-PLEX Human PlGF Assay has the essential components for an assay that measures PlGF in a single-analyte format. For information on multiplexing PlGF with other analytes, please see
U-PLEX Custom Immuno-Oncology Group 1 (human) Assays.
Related Key Terms: placenta growth factor, PGF, PGFL, PLGF, angiogenesis, vasculogenesis, endothelial cell growth, VEGFR-1/flt-1 ligand, monocyte activation, placental trophoblast, angiogenesis
-
-
Specifications
-
Kit Contents
-
-
Documentation
-
References
|
Application(s)
|
|
Cardiovascular
|
|
|
Analyte(s)
|
|
PlGF
|
|
|
Species
|
|
Human
|
|
|
Instrument(s)
|
|
MESO SECTOR S 600MM
,
MESO QuickPlex SQ 120MM
,
MESO QuickPlex Q 60MM
,
MESO SECTOR S 600
,
MESO QuickPlex SQ 120
,
SECTOR Imager 6000
,
SECTOR Imager 2400
|
|
|
U-PLEX Group Compatibility
|
|
Immuno-Oncology Group 1
|
|
|
Plate Type
|
|
96-well
|
|
|
Capture Antibody
|
|
Mouse Monoclonal
|
|
|
Detection Antibody
|
|
Mouse Monoclonal
|
|
|
LLOD (Sensitivity)
|
|
0.19 pg/mL
|
|
|
Dynamic Range
|
|
0.19 - 1,200 pg/mL
|
|
|
Sample Type
|
|
Plasma, Serum
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Gene ID(s)
|
|
5228
|
|
|
UniProt ID(s)
|
|
P49763
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate)
|
|
|
|
|
2-8 °C
|
1 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(8 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(10 mL)
|
|
|
|
|
RT
|
1 bottle
(18 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 each
(1 plate)
|
|
|
|
|
2-8 °C
|
1 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(40 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(50 mL)
|
|
|
|
|
RT
|
1 bottle
(90 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
25 each
(1 plate)
|
|
|
|
|
2-8 °C
|
5 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
5 bottle
(40 mL)
|
|
|
|
|
≤-10 °C
|
5 bottle
(50 mL)
|
|
|
|
|
RT
|
5 bottle
(90 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate)
|
|
|
|
|
2-8 °C
|
1 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(8 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(10 mL)
|
|
|
|
|
RT
|
1 bottle
(18 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 each
(1 plate)
|
|
|
|
|
2-8 °C
|
1 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(40 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(50 mL)
|
|
|
|
|
RT
|
1 bottle
(90 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
25 each
(1 plate)
|
|
|
|
|
2-8 °C
|
5 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
5 bottle
(40 mL)
|
|
|
|
|
≤-10 °C
|
5 bottle
(50 mL)
|
|
|
|
|
RT
|
5 bottle
(90 mL)
|
|
|
|
Product Inserts
|
|
|
|
Datasheets
|
|
|
|
Product Highlights
|
|
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2 in patients with advanced hepatocellular cancer.
|
|
|
|
Phase I study of Dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
|
|
|
|
Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948).
|
|
|
|
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel anti-angiogenesis agent, in two phase I trials in patients with advanced solid tumors.
|
|
|
|
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
|
|
|
|
|
View All
|
Order Details
back
K151B8K
Catalog No
Size
Price in USD
Qty
K151B8K-1
1 plate size
$690.00
K151B8K-2
5 plate size
$2,761.00
K151B8K-4
25 plate size
$12,424.00
K151B8K-21
1 plate size
$690.00
K151B8K-22
5 plate size
$2,761.00
K151B8K-24
25 plate size
$12,424.00
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters